COMMUNIQUÉS West-GlobeNewswire

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
25/02/2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation
25/02/2026
CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or [...]
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
25/02/2026
JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system [...]
Prime Medicine to Participate in Upcoming Investor Conferences
25/02/2026
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Medline Reports Fourth Quarter and Full Year 2025 Results
25/02/2026
Delivered strong full year 2025 results Completed Initial Public Offering Introduced full year 2026 guidance Fourth quarter net sales of $7.8 billion, an increase of 14.8% Fourth quarter net income of $180 million, a [...]
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
25/02/2026
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
25/02/2026
Unlocks market access and growth potential of REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer by enabling adoption and utilization tracking HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus [...]
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
25/02/2026
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
25/02/2026
LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that [...]
Kura Oncology to Participate in Three Upcoming Investor Conferences
25/02/2026
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its [...]
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
25/02/2026
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
25/02/2026
Garching / Munich, February 25, 2026 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced that it will provide further exploratory and post-hoc subgroup analysis [...]
Dyne Therapeutics to Participate in Upcoming Investor Conferences
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery
25/02/2026
Partnership combines Helsinn proprietary compound library with InVirtuoLabs generative AI platform to accelerate discovery of novel therapeutics Lugano, Switzerland – February 25, 2026 – Helsinn Healthcare SA (Helsinn [...]
RYBREVANT®▼ (amivantamab) par voie sous-cutanée, approuvé par la Commission Européenne pour une administration toutes les trois ou quatre semaines chez les patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
25/02/2026
L’amivantamab sous-cutané (SC) réduit l’administration de plusieurs heures à quelques minutes, avec une efficacité et une sécurité comparables à celles de l’amivantamab intraveineux (IV) 1 ,2,3,4,5 L’amivantamab SC est [...]
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
25/02/2026
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of [...]
ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
25/02/2026
The strategic partnership will also support the WHO resolution WHA78.13 with the aim to improve access to medical imaging and nuclear medicine February 25, 2026 – Wiesbaden, Germany. The International Centers for [...]
Novonesis' Annual Report 2025
25/02/2026
Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: ”In 2025, we [...]
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
25/02/2026
Please read the full announcement in PDF Attachment 2026_02_LTI

Pages